June 2, 2020 / 5:21 AM / a month ago

BRIEF-Relief Therapeutics And Neurorx Enroll First Patients With RLF100 In Phase 2B/3 Clinical Trial

June 2 (Reuters) - RELIEF THERAPEUTICS HOLDING SA:

* RELIEF THERAPEUTICS AND NEURORX ANNOUNCE ENROLLMENT OF FIRST PATIENTS WITH RLF100 IN PHASE 2B/3 CLINICAL TRIAL IN PATIENTS WITH COVID-19 ASSOCIATED ACUTE RESPIRATORY DISTRESS

* CLINICAL TRIAL TO ENROLL 144 PATIENTS TOTAL

* PRIMARY ENDPOINTS WILL BE MORTALITY AND INDEX OF RESPIRATORY DISTRESS

* SECONDARY ENDPOINT WILL INCLUDE LEVELS OF TNFA AND MULTI-SYSTEM ORGAN FAILURE FREE DAYS Source text: bit.ly/2XXNbdM Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below